Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Net Cash Flow (2022 - 2025)

Historic Net Cash Flow for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$15.4 million.

  • Taysha Gene Therapies' Net Cash Flow fell 240.45% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.7 million, marking a year-over-year increase of 220737.89%. This contributed to the annual value of -$4.9 million for FY2024, which is 10875.35% down from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Net Cash Flow is -$15.4 million, which was down 240.45% from $196.2 million recorded in Q2 2025.
  • Taysha Gene Therapies' Net Cash Flow's 5-year high stood at $196.2 million during Q2 2025, with a 5-year trough of -$52.5 million in Q1 2022.
  • Its 4-year average for Net Cash Flow is $9.9 million, with a median of -$18.7 million in 2024.
  • Data for Taysha Gene Therapies' Net Cash Flow shows a peak YoY increase of 47326.59% (in 2023) and a maximum YoY decrease of 13803.15% (in 2023) over the last 5 years.
  • Taysha Gene Therapies' Net Cash Flow (Quarter) stood at $53.6 million in 2022, then crashed by 138.03% to -$20.4 million in 2023, then grew by 8.46% to -$18.7 million in 2024, then rose by 17.34% to -$15.4 million in 2025.
  • Its Net Cash Flow was -$15.4 million in Q3 2025, compared to $196.2 million in Q2 2025 and -$22.4 million in Q1 2025.